Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Australia
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)-1-piperazinyl)-, Hydrochloride (1:1)
2. 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide
3. 68843, Emd
4. Emb 68843
5. Emb-68843
6. Emb68843
7. Emd 68843
8. Hcl, Vilazodone
9. Hydrochloride, Vilazodone
10. Viibryd
11. Vilazodone
12. Vilazodone Hcl
1. 163521-08-2
2. Vilazodone Hcl
3. Viibryd
4. Vilazodone (hydrochloride)
5. Emd-68843
6. Emd 68 843
7. Vilazodone Hydrochloride [usan]
8. 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide Hydrochloride
9. Emd 68843
10. U8htx2gk8j
11. Sb659746-a
12. 163521-08-2 (hcl)
13. Chebi:70705
14. Sb659746a
15. 5-[4-[4-(5-cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide Hydrochloride
16. Sb 659746a
17. Sb-659746a
18. Sb-659746-a
19. Vilazodone Hydrochloride (usan)
20. 5-(4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide, Hydrochloride
21. 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide Hydrochloride
22. 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)-1-piperazinyl)-, Hydrochloride (1:1)
23. 5-(4-(4-(5-cyano-1h-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide Monohydrochloride
24. 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride
25. 5-{4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide Hydrochloride
26. Unii-u8htx2gk8j
27. Vilazodonei
28. 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-, Hydrochloride (1:1)
29. Viibryd (tn)
30. Vilazodonehydrochloride
31. Vilazodone Monohydrochloride
32. Schembl867358
33. Chembl1615374
34. Dtxsid80936833
35. Bcp11496
36. Emd68843
37. Mfcd00940014
38. S4259
39. Vilazodone Hydrochloride [mi]
40. Akos024464039
41. Ccg-213313
42. Cs-0549
43. Vilazodone Hydrochloride [mart.]
44. Vilazodone Hydrochloride [vandf]
45. Vilazodone Hydrochloride [who-dd]
46. 5-{4-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboximidic Acid--hydrogen Chloride (1/1)
47. Ac-25885
48. As-74699
49. Emd 68843;sb659746a
50. Hy-14261
51. Vilazodone Hydrochloride, >=98% (hplc)
52. A3919
53. Sw219887-1
54. V0149
55. Vilazodone Hydrochloride [orange Book]
56. D09699
57. 521v128
58. J-525160
59. Q27139037
60. 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine Hydrochloride
61. 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine Hydrochloride
62. 1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine Hydrochloride
63. 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide Hydrochloride
64. 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide Hydrochloride
65. 4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1h-indol-3-yl)butyl]piperazin-1-ium Chloride
66. Vilazodone Hydrochloride Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 478.0 g/mol |
---|---|
Molecular Formula | C26H28ClN5O2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 7 |
Exact Mass | 477.1931528 g/mol |
Monoisotopic Mass | 477.1931528 g/mol |
Topological Polar Surface Area | 102 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 729 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Viibryd |
PubMed Health | Vilazodone (By mouth) |
Drug Classes | Antidepressant |
Drug Label | VIIBRYD Tablets for oral administration contain polymorph Form IV vilazodone hydrochloride (HCl), a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist.Vilazodone HCl is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)... |
Active Ingredient | Vilazodone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Forest Labs |
2 of 2 | |
---|---|
Drug Name | Viibryd |
PubMed Health | Vilazodone (By mouth) |
Drug Classes | Antidepressant |
Drug Label | VIIBRYD Tablets for oral administration contain polymorph Form IV vilazodone hydrochloride (HCl), a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist.Vilazodone HCl is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)... |
Active Ingredient | Vilazodone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Forest Labs |
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)
Selective Serotonin Reuptake Inhibitors
Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)
Serotonin 5-HT1 Receptor Agonists
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes. (See all compounds classified as Serotonin 5-HT1 Receptor Agonists.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
ABOUT THIS PAGE
90
PharmaCompass offers a list of Vilazodone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vilazodone Hydrochloride manufacturer or Vilazodone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vilazodone Hydrochloride manufacturer or Vilazodone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Vilazodone Hydrochloride API Price utilized in the formulation of products. Vilazodone Hydrochloride API Price is not always fixed or binding as the Vilazodone Hydrochloride Price is obtained through a variety of data sources. The Vilazodone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A EMD-68843 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of EMD-68843, including repackagers and relabelers. The FDA regulates EMD-68843 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. EMD-68843 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of EMD-68843 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A EMD-68843 supplier is an individual or a company that provides EMD-68843 active pharmaceutical ingredient (API) or EMD-68843 finished formulations upon request. The EMD-68843 suppliers may include EMD-68843 API manufacturers, exporters, distributors and traders.
click here to find a list of EMD-68843 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A EMD-68843 DMF (Drug Master File) is a document detailing the whole manufacturing process of EMD-68843 active pharmaceutical ingredient (API) in detail. Different forms of EMD-68843 DMFs exist exist since differing nations have different regulations, such as EMD-68843 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A EMD-68843 DMF submitted to regulatory agencies in the US is known as a USDMF. EMD-68843 USDMF includes data on EMD-68843's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The EMD-68843 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of EMD-68843 suppliers with USDMF on PharmaCompass.
A EMD-68843 written confirmation (EMD-68843 WC) is an official document issued by a regulatory agency to a EMD-68843 manufacturer, verifying that the manufacturing facility of a EMD-68843 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting EMD-68843 APIs or EMD-68843 finished pharmaceutical products to another nation, regulatory agencies frequently require a EMD-68843 WC (written confirmation) as part of the regulatory process.
click here to find a list of EMD-68843 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing EMD-68843 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for EMD-68843 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture EMD-68843 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain EMD-68843 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a EMD-68843 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of EMD-68843 suppliers with NDC on PharmaCompass.
EMD-68843 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of EMD-68843 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right EMD-68843 GMP manufacturer or EMD-68843 GMP API supplier for your needs.
A EMD-68843 CoA (Certificate of Analysis) is a formal document that attests to EMD-68843's compliance with EMD-68843 specifications and serves as a tool for batch-level quality control.
EMD-68843 CoA mostly includes findings from lab analyses of a specific batch. For each EMD-68843 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
EMD-68843 may be tested according to a variety of international standards, such as European Pharmacopoeia (EMD-68843 EP), EMD-68843 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (EMD-68843 USP).